Connor, Clark & Lunn Investment Management Ltd. Kronos Bio, Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	SELL	$1.24 - $1.92 $5,547 - $8,590	-4,474 Reduced 16.2%	23,144 $39,000
Q1 2023 May 09, 2023	BUY	$1.34 - $2.62 $2,539 - $4,964	1,895 Added 7.37%	27,618 $40,000
Q4 2022 Feb 10, 2023	BUY	$1.44 - $3.44 $37,041 - $88,487	25,723 New	25,723 $41,000

Others Institutions Holding KRON

# of Institutions

Shares Held

19.8M

Call Options Held

9.3K

Put Options Held

100

Vida Ventures Advisors, LLC

2.77M
Shares

$2.38 Million
3.24% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

2.05M
Shares

$1.76 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

1.92M
Shares

$1.65 Million
0.0% of portfolio
Partners Capital Investment Group, LLP Boston, MA

1.61M
Shares

$1.39 Million
0.03% of portfolio
Alphabet Inc. Mountain View, CA

1.44M
Shares

$1.24 Million
0.1% of portfolio

View Full List

About Kronos Bio, Inc.

Ticker KRON
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,769,100
Market Cap $48.8M
Description
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...

More about KRON

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account